Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
  • Clinical Data

Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns

BioSpace

Right after the FDA flagged safety concerns for Eli Lilly's newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the

Clinical DataMetabolic & GLP-1Read full story

pharminent April 16, 2026 (Last updated: April 16, 2026)

BioSpace

Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the

Clinical DataMetabolic & GLP-1Read full story

Post navigation

Previous: Obesity’s explosive growth continues as Q1 deals exceed total 2025 value
Next: Roche to start new Elevidys study following setback in Europe

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.